MARKET

SPRY

SPRY

ARS Pharms
NASDAQ
9.94
+0.15
+1.53%
Opening 13:31 02/10 EST
OPEN
9.81
PREV CLOSE
9.79
HIGH
10.11
LOW
9.78
VOLUME
324.93K
TURNOVER
--
52 WEEK HIGH
18.90
52 WEEK LOW
6.66
MARKET CAP
982.56M
P/E (TTM)
-11.0297
1D
5D
1M
3M
1Y
5Y
1D
ARS Pharmaceuticals To Present Neffy Clinical Data At AAAAI Annual Scientific Meeting
Benzinga · 8h ago
ARS Pharmaceuticals Unveils New Clinical Data Highlighting neffy Nasal Epinephrine Advantages
Reuters · 8h ago
Weekly Report: what happened at SPRY last week (0202-0206)?
Weekly Report · 1d ago
Aptar posts Q4 adjusted net income of USD 82.1 million
Reuters · 4d ago
AptarGroup meldet für das vierte Quartal einen Nettoertrag von 74,3 Mio. USD, ein Anstieg um 19 Prozent
Reuters · 4d ago
What's Going On With Aquestive Therapeutics Stock After FDA Update For Lead Allergic Treatment?
Benzinga · 02/02 18:12
ARS Pharmaceuticals Gets Positive Opinion For Expanded Marketing Authorization For EURneffy By EMA's Committee For Medicinal Products For Human Use
Benzinga · 02/02 13:18
ARS Pharmaceuticals announces CHMP of EMA adopted positive opinion for EURneffy
TipRanks · 02/02 13:11
More
About SPRY
ARS Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the commercialization and development of neffy for the needle-free intranasal delivery of epinephrine for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an innovative absorption enhancer called Intravail, which allows neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions. Type I allergic reactions are potentially life-threatening hypersensitivity reactions that can occur within minutes of exposure to an allergen and need to be treated immediately to relieve symptoms and prevent further progression.

Webull offers ARS Pharmaceuticals Inc stock information, including NASDAQ: SPRY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SPRY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SPRY stock methods without spending real money on the virtual paper trading platform.